Sorafenib in advanced melanoma: A Phase II randomised discontinuation trial analysis

British Journal of Cancer

Volumn 95, Issue 5, 2006, Pages 581-586

  Eisen, T ^a   Ahmad, T ^a   Flaherty, K T ^b   Gore, M ^a   Kaye, S ^a   Marais, R ^a   Gibbens, I ^a   Hackett, S ^a   James, M ^a   Schuchter, L M ^b   Nathanson, K L ^b   Xia, C ^c   Simantov, R ^c   Schwartz, B ^c   Poulin Costello, M ^c   O'Dwyer, P J ^b   Ratain, M J ^d  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c BAYER CORPORATION   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

Author keywords

Advanced melanoma; Multikinase inhibitor; Randomised discontinuation trial; Sorafenib; V600E BRAF

Indexed keywords

B RAF KINASE; K RAS PROTEIN; PLACEBO; SORAFENIB;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN EMBOLISM; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DNA EXTRACTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FATIGUE; FEMALE; FLUSHING; HUMAN; HYPERTENSION; MALE; MELANOMA; MUTATIONAL ANALYSIS; NAUSEA; NEUROPATHY; ONCOGENE N RAS; PHARYNGITIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN EXFOLIATION; SKIN TOXICITY; STOMATITIS; TUMOR BIOPSY; TUMOR GROWTH; TUMOR VOLUME; WEIGHT REDUCTION; WILD TYPE; WORLD HEALTH ORGANIZATION;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; BENZENESULFONATES; DNA PRIMERS; FEMALE; GENES, RAS; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS B-RAF; PYRIDINES; SAFETY;

EID: 33748325763     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603291     Document Type: Article

References (26)

1. Adnane L, Trail PA, Wilhelm S (2005) Sorafenib (BAY 43-9006) antagonizes Raf function not only by inhibiting Raf kinase activity but also by sequestering Raf protein into non-functional complexes. Presented at AACR-NCI-EORTC, November 2005, Philadelphia, PA
2. Alexandrescu DT, Dutcher JP, Wiernik PH (2005) Metastatic melanoma: is biochemotherapy the future? Med Oncol 22: 101-111
3. Awada A, Hendlisz A, Gil T, Bartholomeus S, Mano M, de Valeriola D, Strumberg D, Brendel E, Haase CG, Schwartz B, Piccart M (2005) Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 92: 1855-1861
4. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, Urist M, McMasters KM, Ross MI, Kirkwood JM, Atkins MB, Thompson JA, Coit DG, Byrd D, Desmond R, Zhang Y, Liu PY, Lyman GH, Morabito A (2001) Prognostic factors analysis of 17 600 melanoma patients: validation of the American Joint Committee on Cancer Melanoma Staging System. J Clin Oncol 19: 3622-3634
5. Britten RA, Klein K (2000) Differential impact of Raf-1 kinase activity on tumor cell resistance to paclitaxel and docetaxel. Anticancer Drugs 11: 439-443
6. Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R, Einhorn E, Herlyn M, Minna J, Nicholson A, Roth JA, Albelda SM, Davies H, Cox C, Brignell G, Stephens P, Futreal PA, Wooster R, Stratton MR, Weber BL (2002) BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 62: 6997-7000
7. Chang DZ, Panageas KS, Osman I, Polsky D, Busam K, Chapman PB (2004) Clinical significance of BRAF mutations in metastatic melanoma. J Transl Med 2: 46
8. Clark JW, Eder JP, Ryan D, Lee R, Lenz H-J (2005) The safety and pharmacokinetics of the multi-targeted tyrosine kinase inhibitor (including Raf kinase and VEGF kinase), BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res 11: 5472-5480
9. Danson S, Lorigan P (2005) Improving outcomes in advanced malignant melanoma: update on systemic therapy. Drugs 65: 733-743
10. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA (2002) Mutations of the BRAF gene in human cancer. Nature 417: 949-954
11. Eisen T, Ahmad T, Marais R, Gibbens I, James M, Affolter A, Chao D, Bergamini L, Schwartz B, Gore ME (2005) Phase I trial of sorafenib (BAY 43-9006) combined with dacarbazine (DTIC) in patients with metastatic melanoma. Eur J Cancer Suppl 3(2): 349
12. Escudier B, Szczylik C, Eisen T, Stadler WM, Schwartz B, Shan M, Bukowski RM (2005) Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). J Clin Oncol 23(16_suppl): LBA4510 1-6-2005
13. Flaherty KT, Brose M, Schuchter L, Tuveson D, Lee R, Schwartz B, Lathia C, Weber B, O'Dwyer P (2004) Phase I/II trial of BAY 43-9006, carboplatin (C) and paclitaxel (P) demonstrates preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma. J Clin Oncol 22(14S): 7507 (Abstract), 15-7-2004
14. Garnett MJ, Marais R (2004) Guilty as charged: B-RAF is a human oncogene. Cancer Cell 6: 313-319
15. Hingorani SR, Jacobetz MA, Robertson GP, Herlyn M, Tuveson DA (2003) Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res 63: 5198-5202
16. Karasarides M, Chiloeches A, Hayward R, Niculescu-Duvaz D, Scanlon I, Friedlos F, Ogilvie L, Hedley D, Martin J, Marshall CJ, Springer CJ, Marais R (2004) B-RAF is a therapeutic target in melanoma. Oncogene 23: 6292-6298
17. Panka DJ, Wang W, Atkins MB, Mier JW (2006b) The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells. Cancer Res 66: 1611-1619
18. Panka DJ, Wang W, Atkins MB, Mier JW (2006a) The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells. Cancer Res 66: 1611-1619
19. Rahmani M, Maynard Davis E, Bauer C, Dent P, Grant S (2005) Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves downregulation of mcl-1 through inhibition of translation. J Biol Chem 280: 35217-35227
20. Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, Gore M, Desai AA, Patnaik A, Xiong HQ, Rowinsky E, Abbruzzese JL, Xia C, Simantov R, Schwartz B, O'Dwyer PJ. Related articles, links phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24(16): 2505-2512
21. Ratain MJ, Flaherty KT, Stadler WM, O'Dwyer P, Kaye S, Xiong H, Patnaik A, Gore M, Lee RJ, Eisen T (2004) Preliminary antitumor activity of BAY 43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial (RDT). J Clin Oncol 22: 381 (Abstract 4501). See also oral presentation at www.asco.org/
22. Satyamoorthy K, Li G, Gerrero MR, Brose MS, Volpe P, Weber BL, Van Belle P, Elder DE, Herlyn M (2003) Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res 63: 756-759
23. Strumberg D, Awada A, Piccart P, Hirte H, Moore M, Clark J, Lenz H-J, Lathia C, Schwartz B, Humphrey R (2003) Final report of the phase I clinical program of the novel raf kinase inhibitor BAY 43-9006 in patients with refractory solid tumors. J Clin Oncol 22: 203
24. Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M, Faghih M, Brendel E, Voliotis D, Haase CG, Schwartz B, Awada A, Voigtmann R, Scheulen ME, Seeber S (2005) Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 23: 965-972
25. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA (2004) BAY 43-9006 exhibits broad spectrum oral anti-tumor activity and targets the Raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64: 7099-7109
26. Yu C, Bruzek LM, Meng XW, Gores GJ, Carter CA, Kaufmann SH, Adjei AA (2005) The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene 24: 6861-6869